Overview

Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma

Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to study the benefits of giving chemotherapy to women after they have had surgical resection of their primary disease and have no evidence of disease remaining(known as adjuvant therapy). The major objective of this study is to determine the progression free survival. The goal is to prevent relapse or recurrence of their uterine leiomyosarcoma.
Phase:
Phase 2
Details
Lead Sponsor:
Sarcoma Alliance for Research through Collaboration
Treatments:
Docetaxel
Doxorubicin
Gemcitabine
Liposomal doxorubicin